Phase 2 Study of NGM282 in Patients With Type 2 Diabetes

Phase 2CompletedNCT01943045

NGM Biopharmaceuticals, Inc81 enrolled

Overview

The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Type 2 Diabetes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Diabetes Mellitus

Interventions

NGM282BIOLOGICAL

PlaceboOTHER

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Males or females, between 18 and 70 years of age, inclusive * BMI range of 24-40 kg/m2, inclusive * No active coronary artery disease * Resting heart rate in the range of 40-100 bpm Exclusion Criteria: * Diagnosis of Type 1 diabetes * History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance

Locations (9)

NGM Clinical Study Site 6103

Melbourne, Victoria, Australia

NGM Clinical Study Site 6104

Melbourne, Victoria, Australia

NGM Clinical Study Site 6101

Perth, Western Australia, Australia

NGM Clinical Study Site 6403

Auckland, New Zealand

Outcomes

Primary Outcomes

Fasting Plasma Glucose

Time frame: 28 days

Secondary Outcomes

HbA1c

Time frame: 28 days

Lipids

Time frame: 28 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.